- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04590222
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 (MAOi-COV19)
Study Overview
Detailed Description
Investigators want to test in vitro (in France Stage 1), and in vivo in a phase 1b/2 clinical trial (Stage 2 in Australia) a widely used antidepressant (the monoamine oxidase inhibitor (MAOi) Phenelzine (Nardil*), repurposed as an antiviral drug to treat SARS-CoV-2. Indeed this proposal leverages extensive existing data on the epigenetic mechanism of action of phenelzine and new data suggesting that it has an anti-viral action against the SARS-CoV-2 virus.
Epigenetic drugs are promising antiviral treatments capable of modifying epigenetic tags and re-programming host and viral genomes. Epigenetic modulation could be useful at least at two steps: the entry of the virus, and the regulation of the immune response. The SARS-Cov-2 depends on ACE2 and TMPRSS2 to gain cellular entry. The reduction of the expression of these proteins could therefore be protective.
Recent clinical studies have demonstrated that, in addition to their effects on neurotransmitter regulation, anti-depressants also possess anti-inflammatory characteristics via impacting pro inflammatory cytokines production which are involved in the 'cytokines storm' during severe disease. (2). These patients also have fewer circulating functional T cells and NK cells and greater numbers of dysfunctional, exhausted CD8+ T cells (3). These abnormalities are probably deleterious and reduce the efficacy of anti-viral responses.
The in-depth and patented epigenetic, cellular, and structural analyses of human cell lines harbouring the SARS-CoV-2 infective machinery and capable of propagating the virus have shown that:
- The epigenetic enzyme (histone demethylase) LSD1 directly regulates the SARS-CoV-2-binding domain of ACE2 and the protease active sites of TMPRSS2 (patented), which are critical for viral entry and propagation within the host.
- MAOi, which target LSD1 activity, inhibit the ACE2/TMPRSS2 machinery, which investigators hypothesize will prevent viral entry into the host cell to reduce viral load, disease burden, and the emergence of cytokine storms. In support of novel dual targeting viral blockage strategy recent work have shown that targeting TMPRSS2 or ACE2 alone has anti-viral activity (4).
LSD1 inhibition with Phenelzine in recent, successfully completed phase 1B clinical demonstrate that Phenelzine reverses the dysfunctional T cell phenotype and restores durable memory responses in vivo in advanced, metastatic breast cancer patients. Importantly, no adverse impact on healthy volunteer immune systems was recorded as part of the phase 1B clinical trial (5). Preclinical data shows that aged individuals have exhausted T cells compared to young individuals and MAOi re-waken these T cells resembling younger people.
Thus, investigators propose that in patients with severe COVID-19 infection, who are predominantly elderly; where dysfunctional T cells is also a feature, Phenelzine would have additional benefits on their immune function without adverse effects.
Therefore, this proposal exploits a clear mechanism of action of Phenelzine: epigenetic regulation and is the first study to explore epigenetic mechanisms in SARS-CoV-2 infection. Modulation of the epigenetism could directly counteract the virus via an antiviral effect, and indirectly via the restoration of a functional immune response.
Phenelzine has been used for nearly 60 years to treat major depressive disorder. Its side-effects, most of which are minor, are well characterized, including in the elderly or immune vulnerable.
Investigators approach is highly flexible, since LSD1 inhibition targets two immune mechanisms - a specific viral uptake pathway and the efficacy of T cell responses. Give the safety and easy applicability of Phenelzine, it lends itself to combinatorial therapeutic approaches as and when other anti-viral show efficacy. From the mechanistic perspective, investigators epigenetic approach complements and contextualises genetic studies on COVID-19.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Olivier LAMBOTTE, Prof
- Phone Number: 33 1 45 21 22 05
- Email: olivier.lambottte@aphp.fr
Study Contact Backup
- Name: Katia BOURDIC
- Phone Number: 33 1 45 21 63 16
- Email: katia.bourdic@aphp.fr
Study Locations
-
-
-
Le Kremlin-Bicêtre, France, 94270
- Recruiting
- CHU Bicêtre
-
Contact:
- Olivier LAMBOTTE, Prof
- Email: olivier.lambotte@aphp.fr
-
Contact:
- Katia BOURDIC
- Email: katia.bourdic@aphp.fr
-
Principal Investigator:
- Olivier LAMBOTTE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1. Individuals male or female ≥18 years of age at time of enrolment
- 2.Subject (or legally authorized representative provides non opposition form prior to initiation of any study procedure.
- 3. Understands and agrees to comply with planned study procedure. (Agrees to the collection of venous blood per protocol).
- 4. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen<72hours prior to enrollment and/or a chest CT scan reported as highly likely SARS-CoV2 infection.
The different scales for severity are as follows:
- 5. Non severe patients: Clinical assessment (evidence of rales/crackles on exam) or CT scan involvement AND SpO2> 94% on room air, or ≤ 94% on room air but > 94% with nasal Oxygen with a flow rate <= 3l O2/min
For the severe infection's patients' group:
- 6. Patients requiring mechanical ventilation and/or supplemental oxygen >= 6l O2/min
For the obese patients 'group:
- 7. Obese patients will be defined as an BMI > 30
- 8. Co inclusion in non-interventional researches is possible
Exclusion Criteria:
- Pregnant and breast-feeding women
- Patients previously treated by phenelzine (Nardil®)
- Persons unable to give their no opposition
- Persons under guardianship or curatorship
- No affiliated to social insurance.
- Inclusion in interventional researches
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Female, BMI≥30, mild
Females: Obese BMI≥30 With Mild infection n = 10 |
One blood sample of 60 mL (EDTA)
|
Female, BMI≥30, severe
Females: Obese BMI≥30 With severe infection n = 10 |
One blood sample of 60 mL (EDTA)
|
Female, BMI<30, mild
Females: Non-Obese BMI<30 With Mild infection n = 10 |
One blood sample of 60 mL (EDTA)
|
Female, BMI<30, severe
Females: Non-Obese BMI<30 With severe infection n = 10 |
One blood sample of 60 mL (EDTA)
|
male, BMI≥30, mild
males: Obese BMI≥30 With Mild infection n = 10
|
One blood sample of 60 mL (EDTA)
|
male, BMI≥30, severe
males: Obese BMI≥30 With severe infection n = 10
|
One blood sample of 60 mL (EDTA)
|
male, BMI<30, mild
males: Non-Obese BMI<30 With Mild infection n = 10
|
One blood sample of 60 mL (EDTA)
|
male, BMI<30, severe
males: Non-Obese BMI<30 With severe infection n = 10
|
One blood sample of 60 mL (EDTA)
|
Healthy donors from the EFS (Etablissement Français du Sang, St Louis)
Healthy donors from the EFS (Etablissement Français du Sang, St Louis) including 5 men and 5 women
|
One blood sample of 60 mL (EDTA)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
levels of lymphocytes T DR + CD38 + and of monocytes CD14 dim + CD16 +.
Time Frame: through study completion, an average of 1 year
|
evaluate the levels of the activation of T cells and myeloid cells after phenelzine exposure by the levels of the % of DR+ CD38+ T cells and CD14+dim CD16+ monocytes.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of immune checkpoints
Time Frame: through study completion, an average of 1 year
|
evaluate the levels of the expression of immune checkpoints on T cells by flow cytometry
|
through study completion, an average of 1 year
|
cytokine production and proliferation
Time Frame: through study completion, an average of 1 year
|
evaluate the modification of functional capacities of T cells by cytokines production, and proliferation, after mitogenic and antigen recall stimulations including SARS-CoV-2 antigens
|
through study completion, an average of 1 year
|
levels of neutrophils
Time Frame: through study completion, an average of 1 year
|
assess if there is an impact of phenelzine on the activation levels of neutrophils
|
through study completion, an average of 1 year
|
level of immune responses in obese patients
Time Frame: through study completion, an average of 1 year
|
Determine if the immune responses in obese patients (a strong risk factor for severe Covid19) can be modulated in the same way compared with lean patients
|
through study completion, an average of 1 year
|
level of immune responses for men and women
Time Frame: through study completion, an average of 1 year
|
Determine if the immune responses can be modulated in the same way in men and in women (men being affected by more severe disease)
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Olivier LAMBOTTE, Prof, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP200989
- 2020-A02398-31 (OTHER: IDRCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV2 Infection
-
Centre Hospitalier Universitaire DijonUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleFondation Santé RoquetteCompleted
-
University of AarhusCompleted
-
University Hospital, LilleFondation Santé RoquetteUnknown
-
Medical University of ViennaWithdrawnSars-CoV2 | Prophylaxis | Infection Viral | Healthcare Worker
-
Colorado School of Public HealthUniversity of Colorado, Denver; University of Colorado, Boulder; Colorado State... and other collaboratorsRecruitingCOVID-19 | SARS-CoV2 InfectionUnited States
Clinical Trials on blood sample
-
Medical University of WarsawCompletedArthroplasty | Platelet Aggregation | Methylmethacrylate EmbolismPoland
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Meir Medical CenterCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingComplication | Hematologic Malignancy | Hematopoietic Stem Cell Transplantation | Chronic Graft-versus-host-diseaseChina
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruitingImmune Thrombocytopenia | Autoimmune Hemolytic Anemia | Autoimmune NeutropeniaFrance
-
University Hospital, ToursCompletedMetastatic Prostate Cancer | Circulating Tumor DNAFrance
-
University Hospital, BordeauxActive, not recruitingSystemic Lupus Erythematosus | Systemic SclerodermaFrance
-
University Hospital, BordeauxCompletedRenal Function Disorder | Chronic Renal Diseases
-
University Hospital, ToursNot yet recruitingRenal Transplant | ConversionFrance